Poland· PL-100443846
Phesgo
A pertuzumab und trastuzumab product containing trastuzumabum + pertuzumabum, registered in Poland by Roche Registration GmbH. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Pertuzumab und trastuzumab is registered in 10 of 19 countries.
Countries holding a registration under ATC L01FY01 (pertuzumab und trastuzumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Pertuzumab und trastuzumab · ATC L01FY01
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Trastuzumabum + Pertuzumabum
- Manufacturer
- Roche Registration GmbH
- Country
- Poland (PL)
- ATC code
- L01FY01
- ATC class
- Pertuzumab und Trastuzumab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07613326036191
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Pertuzumab und trastuzumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPHESGORoche Registration GmbH, Grenzach-Wyhlen
- SpainPHESGO 1200 MG/600 MG SOLUCION INYECTABLERoche Registration Gmbh
- FinlandPhesgoAbacus Medicine A/S
- CanadaPERJETA-HERCEPTINHOFFMANN-LA ROCHE LIMITED
- FrancePHESGO 1200 mg/600 mg, solution injectableROCHE REGISTRATION (ALLEMAGNE)
- United KingdomPhesgo 1200mg/600mg/15ml solution for injection vialsRoche Products Ltd
- IrelandPhesgo 1200 mg/600 mg solution for injectionRoche Registration GmbH
- IcelandPhesgoRoche Registration GmbH*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Phesgo
- Liechtenstein · Phesgo
- Norway · Phesgo
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/8268a3e7-984f-4953-9e8d-63a84d09cf33 GET /v1/drugs/8268a3e7-984f-4953-9e8d-63a84d09cf33?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Roztwór do wstrzykiwań",
"source": "urpl",
"strength": "600 mg + 600 mg",
"packaging": "07613326036191 ¦ Rpz ¦ EU/1/20/1497/002 ¦ 138436\n1 fiol. 10 ml",
"substance": "Trastuzumabum 600 mg + Pertuzumabum 600 mg",
"common_name": "Trastuzumabum + Pertuzumabum",
"pl_product_id": "100443846",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about pertuzumab und trastuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.